Keros Therapeutics, Inc.
Financials
Valuation Metrics
Keros Therapeutics, Inc.'s Market Cap is $213M. At end of 2025 it was $758M. Ranked #2969 of 3,118 in US market (top 95%), #1354 of 1,474 on NASDAQ (top 92%), #243 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $213M | US#2,969/3,118 Sec#243/265 |
| Revenue | $15M | US#2,792/3,118 Sec#163/265 |
| Net Income | $-83M | US—/3,118 Sec—/265 |
| Total Assets | $288M | US#2,908/3,118 Sec#210/265 |
| Net Assets | $262M | US#2,568/3,118 Sec#162/265 |
| Employees | 92 | US#2,630/3,118 Sec#183/265 |
| Value | ||
| P/B | 0.81x | US#278/3,118 Sec#12/265 |
| P/S | 14.18x | US#2,795/3,118 Sec#134/265 |
| FCF Yield | -22.77% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -31.70% | US#2,570/3,118 Sec#116/265 |
| ROA | -28.91% | US#2,865/3,118 Sec#152/265 |
| Op. Margin | -675.82% | US#2,789/3,118 Sec#158/265 |
| Revenue Growth | -93.55% | US#2,720/3,118 Sec#178/265 |
| Earnings Growth | -542.97% | US#1,978/3,118 Sec#66/265 |
| Financial Health | ||
| Debt Ratio | 9.64% | US#104/3,118 Sec#50/265 |
| Total Debt | $16M | US#2,773/3,118 Sec#193/265 |
| FCF | $-48M | US#2,520/3,118 Sec#113/265 |
| Cash | $258M | US#1,536/3,118 Sec#93/265 |
| Current Ratio | 21.96x | US#106/3,118 Sec#19/265 |
| Performance | ||
| 1Y Return | -29.30% | US#2,544/3,118 Sec#201/265 |
| 1M Return | -5.28% | US#2,053/3,118 Sec#138/265 |
| From 52W High | -52.28% | US#2,653/3,118 Sec#200/265 |
| 1Y MDD | -54.62% | US#2,560/3,118 Sec#186/265 |
| Trading | ||
| Volume | 138,847 shares | US#2,829/3,118 Sec#258/265 |
| Trading Value | $2M | US#2,955/3,118 Sec#250/265 |
| Per Share | ||
| EPS | $-4.20 | US—/3,118 Sec—/265 |
| BPS | $13.25 | US#1,623/3,118 Sec#51/265 |
Company Info
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.